Search

Displaying results 1851 - 1860 of 5419 in total
  1. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    [A252672] The drug was first approved by the FDA in September 2022.[L43217]

  2. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. … Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.

  3. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  4. Drug

    Dinoprostone

    go.drugbank.com/drugs/DB00917
    ApprovedInvestigational

    It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.

  5. Drug

    Zinc

    go.drugbank.com/drugs/DB01593
    ApprovedInvestigational

    It is identified by the symbol _Zn_ [L2098].

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  6. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation

  7. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

  8. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  9. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. … [A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery.

  10. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.